Equipment Supplement Requisition for Mesoscale Quick Plex SQ 120mm Reader

此购买设备的行政补充申请是根据PA-18-591提交的 (NIGMS设备管理补充计划)。我目前资助的R01 GM122934是 此补充请求的父级奖励。我正在申请中尺度QuickPlex SQ的资金 120.危重病人经常出现复杂的疾病谱，可能包括全身性 炎症反应综合征、败血症综合征、感染性休克和/或多器官功能障碍 综合症。在美国，每年约有951,000名患者患上脓毒症，其中约一半 ICU里的病人。总死亡率为28.6%。那些在最初的败血症事件中幸存下来的患者 可能最终由于持续的免疫功能障碍而死于广泛的器官功能障碍。这很好 公认败血症会导致免疫系统的抑制，而败血症导致的免疫麻痹 使危重病人容易继发感染。继发性真菌感染是最常见的 严重，因为它们很难诊断和治疗。试图开发有效的治疗方法来预防或 治疗脓毒症及其相关的免疫抑制已被证明是极其困难的。事实上，没有毒品 目前已被FDA批准用于脓毒症的治疗。这项研究的一个非常重要的方面 目的是确定脓毒症对白细胞和先天免疫参数的影响。要做到这一点 目的：我们将对脓毒症患者的细胞因子、趋化因子和生物标志物进行批判性分析。这将需要 探测灵敏度和动态范围远远超出了我们目前的能力。中尺度 本补充资料中要求的QuickPlex SQ 120将满足这一关键且未得到满足的需求。此外， SQ 120能力的增强将使我们能够更严格地评估我们的工作假设。

This administrative supplement request to purchase equipment is being submitted in response to PA-18-591 (NIGMS Program of Administrative Supplements for Equipment). My currently funded R01 GM122934 is the parent award for this supplemental request. I am requesting funding for a Mesoscale QuickPlex SQ 120. The critically ill patient frequently develops a complex disease spectrum that may include systemic inflammatory response syndrome, sepsis syndrome, septic shock and/or multiple organ dysfunction syndrome. In the United States ~951,000 patients/year develop sepsis with approximately half of these patients in the ICU. The overall mortality rate is 28.6%. Those patients that survive the initial septic event may ultimately succumb to widespread organ dysfunction due to ongoing immune dysfunction. It is well accepted that sepsis causes suppression of the immune system, and that sepsis-induced immunoparalysis predisposes the critically ill patient to secondary infections. Secondary fungal infections are one of the most serious, as they are difficult to diagnose and treat. Attempts at developing effective therapies to prevent or treat sepsis and its associated immunosuppression have proven to be exceedingly difficult. In fact, no drugs are currently approved by the FDA for the management of sepsis. A very important aspect of this research is to establish the impact of sepsis on leukocytes and innate immune parameters in sepsis. To achieve this goal, we will critically analyze cytokines, chemokines and biomarkers from sepsis patients. This will require a detection sensitivity and dynamic range that is far beyond our current capabilities. The Mesoscale QuickPlex SQ 120 that is requested in this supplement will fill this critical and unmet need. In addition, the increase capabilities of the SQ 120 will allow us to more critically evaluate our working hypotheses.